Hanseong Kim1,*, Sojin An1,*, Seung-Hyun Ro2,*,†,, Filipa Teixeira3,4,5,6, Gyeong Jin Park1,7, Cheal Kim7, Chun-Seok Cho2, Jeong-Sig Kim2,8, Ursula Jakob1,3, Jun Hee Lee2 & Uhn-Soo Cho1
1 Department of Biological Chemistry, University of Michigan, Ann Arbor, Michigan 48109, USA. 2 Department of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, Michigan 48109, USA. 3 Department of Molecular, Cellular and Developmental Biology, University of Michigan, Ann Arbor, Michigan 48109, USA. 4Infection and Immunity Unit, Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200 Porto, Portugal. 5 IBMC- Instituto de Biologia Molecular e Celular, Universidade do Porto, 4150-180 Porto, Portugal. 6ICBAS—Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, 4050-313 Porto, Portugal. 7 Department of Fine Chemistry, Seoul National University of Science and Technology, Seoul 139-743, Korea.8 Department of Obsterics and Gynecology, Soonchunhyang University Seoul Hospital, Seoul 140-743, Korea.
* These authors contributed equally to this work.
† Present address: Department of Biochemistry, University of Nebraska-Lincoln, Lincoln, Nebraska 68588, USA.
Correspondence to : Jun Hee Lee or Uhn-Soo Cho
Abstract
Sestrins are stress-inducible metabolic regulators with two seemingly unrelated but physiologically important functions: reduction of reactive oxygen species (ROS) and inhibition of the mechanistic target of rapamycin complex 1 (mTORC1). How Sestrins fulfil this dual role has remained elusive so far. Here we report the crystal structure of human Sestrin2 (hSesn2), and show that hSesn2 is twofold pseudo-symmetric with two globular subdomains, which are structurally similar but functionally distinct from each other. While the N-terminal domain (Sesn-A) reduces alkylhydroperoxide radicals through its helix-turn-helix oxidoreductase motif, the C-terminal domain (Sesn-C) modified this motif to accommodate physical interaction with GATOR2 and subsequent inhibition of mTORC1. These findings clarify the molecular mechanism of how Sestrins can attenuate degenerative processes such as aging and diabetes by acting as a simultaneous inhibitor of ROS accumulation and mTORC1 activation.